The Claim
In adults with type 2 diabetes and obesity (BMI 28–40), monthly intravenous administration of bimagrumab (10 mg/kg) for 48 weeks causes a 20.5% reduction in total body fat mass, a 3.6% increase in lean mass, and a net 6.5% decrease in body weight.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes and obesity, monthly intravenous injections of bimagrumab for 48 weeks reduce total body fat by 20.5%, increase lean mass by 3.6%, and lower overall body weight by 6.5%.
See the scientific wording
In adults with type 2 diabetes and obesity (BMI 28–40), monthly intravenous bimagrumab (10 mg/kg) for 48 weeks causes a 20.5% reduction in total body fat mass and a 3.6% increase in lean mass, with a net 6.5% decrease in body weight, demonstrating a unique pharmacologic effect of simultaneously reducing adiposity while increasing muscle mass.
A drug blocks a signal that normally stops muscle growth, so muscles get bigger. At the same time, fat tissue starts burning more energy, so fat decreases. The body loses weight because it gains muscle and loses fat at the same time.
What the research says
1 studyStudy: Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
In a well-run study, people with type 2 diabetes and obesity who got monthly bimagrumab shots lost 20% of their body fat, gained 3.6% more muscle, and lost 6.5% of their total weight — all without changing their diet or exercise much. The study proves the drug does exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.